Merck's (MRK) KEYTRUDA (pembrolizumab) Demonstrates Improved OS at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE